Hedia and Glooko Collaborate to Enhance Diabetes Management with Personalized Insulin Dosing
In a significant move for diabetes management, Glooko, Inc. and Hedia have announced the launch of their interoperable solution designed to enhance connected care, patient monitoring, and the utilization of digital therapeutic technologies. This partnership aims specifically at benefiting individuals with Type 1 and Type 2 diabetes who require advanced bolus insulin dosing to assist in their daily management routines.
The newly introduced solution is currently being rolled out in the UK, with plans to expand into other European countries shortly. In diabetes care, a bolus refers to an additional dose of insulin that is administered to manage expected rises in blood glucose levels, typically before meals or snacks. Generally, it is accepted that one unit of insulin is needed to reduce blood sugar levels by approximately 50 mg/dL, though this can vary widely among individuals. This variability poses a challenge for many patients, especially those relying on multiple daily injections rather than insulin pumps.
Glooko's platform allows users to share their diabetes-related data securely with healthcare providers. This information includes glucose readings, insulin doses, food and carbohydrate intake, physical activities, blood pressure, and weight. By integrating the Hedia Diabetes Assistant into its system, Glooko enhances personalized support for users, simplifying insulin dosage calculations and facilitating improved diabetes management.
Healthcare professionals also stand to gain from this collaboration. The integration provides them with better insights into their patients’ health data, offering convenient access to important metrics like blood sugar levels, insulin doses, carbohydrate intake, and physical activity. This innovative approach to managing multiple daily injections not only improves patient outcomes but also enhances the efficiency of outpatient and inpatient care.
According to Mike Alvarez, the CEO of Glooko, this collaboration with Hedia introduces a personalized, algorithm-driven solution that empowers diabetes patients and their healthcare providers. 'Backed by extensive clinical data demonstrating the efficacy of Hedia’s technology, this solution provides an alternative for those without access to insulin pumps, ensuring a more effective management approach for multiple daily injections. Our partnership reflects Glooko's commitment to advancing digital health tools that optimize diabetes care and stabilize blood sugar levels through personalized, connected healthcare,' he stated.
Lars Christian Lund, the CEO of Hedia, emphasized the alignment of this initiative with Hedia’s mission to enhance the quality of life for people with diabetes. 'Our collaboration with Glooko, a digital health company with a robust clinical network, positions us to provide the best tools for managing diabetes. In addition to compelling clinical evidence, compliance with regulatory standards has always been a priority for us. Hedia recently received MDR certification in Europe, classifying our product as a Class IIb medical device, ensuring that patients and their care teams receive the best solutions available,' he noted.
Hedia is a pioneering digital therapy company focused on diabetes, particularly insulin-dependent diabetes. The driving force behind the development of the Hedia Diabetes Assistant is to make life easier for those living with diabetes. The application generates insulin dosage recommendations tailored to the unique habits and individual input of each diabetic user while considering various aspects of diabetes management, from blood glucose monitoring to tracking active insulin and carbohydrate consumption.
Glooko is dedicated to improving health outcomes for individuals with chronic conditions through its intelligent, personalized connected care and life sciences platform. Glooko's well-established technologies revolutionize the connection between patients and providers, enhancing patient engagement and adherence to therapy through digital interventions while accelerating clinical trials. Globally, Glooko's services are utilized in over 30 countries across more than 10,000 clinical locations, with over 4.4 million individuals having benefited from the platform. More information is available on glooko.com.
The newly introduced solution is currently being rolled out in the UK, with plans to expand into other European countries shortly. In diabetes care, a bolus refers to an additional dose of insulin that is administered to manage expected rises in blood glucose levels, typically before meals or snacks. Generally, it is accepted that one unit of insulin is needed to reduce blood sugar levels by approximately 50 mg/dL, though this can vary widely among individuals. This variability poses a challenge for many patients, especially those relying on multiple daily injections rather than insulin pumps.
Glooko's platform allows users to share their diabetes-related data securely with healthcare providers. This information includes glucose readings, insulin doses, food and carbohydrate intake, physical activities, blood pressure, and weight. By integrating the Hedia Diabetes Assistant into its system, Glooko enhances personalized support for users, simplifying insulin dosage calculations and facilitating improved diabetes management.
Healthcare professionals also stand to gain from this collaboration. The integration provides them with better insights into their patients’ health data, offering convenient access to important metrics like blood sugar levels, insulin doses, carbohydrate intake, and physical activity. This innovative approach to managing multiple daily injections not only improves patient outcomes but also enhances the efficiency of outpatient and inpatient care.
According to Mike Alvarez, the CEO of Glooko, this collaboration with Hedia introduces a personalized, algorithm-driven solution that empowers diabetes patients and their healthcare providers. 'Backed by extensive clinical data demonstrating the efficacy of Hedia’s technology, this solution provides an alternative for those without access to insulin pumps, ensuring a more effective management approach for multiple daily injections. Our partnership reflects Glooko's commitment to advancing digital health tools that optimize diabetes care and stabilize blood sugar levels through personalized, connected healthcare,' he stated.
Lars Christian Lund, the CEO of Hedia, emphasized the alignment of this initiative with Hedia’s mission to enhance the quality of life for people with diabetes. 'Our collaboration with Glooko, a digital health company with a robust clinical network, positions us to provide the best tools for managing diabetes. In addition to compelling clinical evidence, compliance with regulatory standards has always been a priority for us. Hedia recently received MDR certification in Europe, classifying our product as a Class IIb medical device, ensuring that patients and their care teams receive the best solutions available,' he noted.
About Hedia
Hedia is a pioneering digital therapy company focused on diabetes, particularly insulin-dependent diabetes. The driving force behind the development of the Hedia Diabetes Assistant is to make life easier for those living with diabetes. The application generates insulin dosage recommendations tailored to the unique habits and individual input of each diabetic user while considering various aspects of diabetes management, from blood glucose monitoring to tracking active insulin and carbohydrate consumption.
About Glooko
Glooko is dedicated to improving health outcomes for individuals with chronic conditions through its intelligent, personalized connected care and life sciences platform. Glooko's well-established technologies revolutionize the connection between patients and providers, enhancing patient engagement and adherence to therapy through digital interventions while accelerating clinical trials. Globally, Glooko's services are utilized in over 30 countries across more than 10,000 clinical locations, with over 4.4 million individuals having benefited from the platform. More information is available on glooko.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.